187 related articles for article (PubMed ID: 22252658)
1. Pancreatic cancer: the role of molecular markers in diagnosis and management.
Lowery MA; O'Reilly EM
Clin Adv Hematol Oncol; 2011 Dec; 9(12):900-8. PubMed ID: 22252658
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Pancreatic Cancer: Novel Prognostic Biomarkers and Targeted Therapy-A Review of the Literature.
Schlick K; Kiem D; Greil R
Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680101
[TBL] [Abstract][Full Text] [Related]
3. Limitations in improving detection of pancreatic adenocarcinoma.
Mendieta Zerón H; García Flores JR; Romero Prieto ML
Future Oncol; 2009 Jun; 5(5):657-68. PubMed ID: 19519205
[TBL] [Abstract][Full Text] [Related]
4. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives.
Wang S; Zheng Y; Yang F; Zhu L; Zhu XQ; Wang ZF; Wu XL; Zhou CH; Yan JY; Hu BY; Kong B; Fu DL; Bruns C; Zhao Y; Qin LX; Dong QZ
Signal Transduct Target Ther; 2021 Jul; 6(1):249. PubMed ID: 34219130
[TBL] [Abstract][Full Text] [Related]
5. Molecular detection of pancreatic neoplasia: Current status and future promise.
Majumder S; Chari ST; Ahlquist DA
World J Gastroenterol; 2015 Oct; 21(40):11387-95. PubMed ID: 26526068
[TBL] [Abstract][Full Text] [Related]
6. Identification of prognostic and predictive markers in pancreatic adenocarcinoma. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Russo SM; Ove R; Saif MW
JOP; 2011 Mar; 12(2):92-5. PubMed ID: 21386628
[TBL] [Abstract][Full Text] [Related]
7. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathobiology of pancreatic adenocarcinoma.
Mangray S; King TC
Front Biosci; 1998 Nov; 3():D1148-60. PubMed ID: 9820739
[TBL] [Abstract][Full Text] [Related]
10. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
Adv Exp Med Biol; 2015; 889():71-87. PubMed ID: 26658997
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of biomarkers in the management of pancreatic adenocarcinoma.
Jazieh KA; Foote MB; Diaz LA
Semin Radiat Oncol; 2014 Apr; 24(2):67-76. PubMed ID: 24635863
[TBL] [Abstract][Full Text] [Related]
12. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
[TBL] [Abstract][Full Text] [Related]
13. Targeting microRNAs in pancreatic cancer: microplayers in the big game.
Khan S; Ansarullah ; Kumar D; Jaggi M; Chauhan SC
Cancer Res; 2013 Nov; 73(22):6541-7. PubMed ID: 24204026
[TBL] [Abstract][Full Text] [Related]
14. Proteomic strategies in the search for novel pancreatic cancer biomarkers and drug targets: recent advances and clinical impact.
Coleman O; Henry M; McVey G; Clynes M; Moriarty M; Meleady P
Expert Rev Proteomics; 2016; 13(4):383-94. PubMed ID: 26985644
[TBL] [Abstract][Full Text] [Related]
15. How can next-generation diagnostics aid pancreatic adenocarcinoma treatment?
Zhang SQ; Catenacci DV
Future Oncol; 2016 Mar; 12(5):585-8. PubMed ID: 26831761
[No Abstract] [Full Text] [Related]
16. Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.
Chang JC; Kundranda M
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28335509
[TBL] [Abstract][Full Text] [Related]
17. Molecular Analysis of Vascular Endothelial Growth Factor (VEGF) Receptors in EUS-guided Samples Obtained from Patients with Pancreatic Adenocarcinoma.
Costache MI; Iordache S; Costache CA; Dragos E; Dragos A; Saftoiu A
J Gastrointestin Liver Dis; 2017 Mar; 26(1):51-57. PubMed ID: 28338114
[TBL] [Abstract][Full Text] [Related]
18. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
Brancaccio M; Natale F; Falco G; Angrisano T
Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31877923
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Drewes AM; Pedersen IS; Krarup H; Thorlacius-Ussing O
Clin Epigenetics; 2016; 8():117. PubMed ID: 27891190
[TBL] [Abstract][Full Text] [Related]
20. Gene overexpression in pancreatic adenocarcinoma: diagnostic and therapeutic implications.
Rodriguez JA; Li M; Yao Q; Chen C; Fisher WE
World J Surg; 2005 Mar; 29(3):297-305. PubMed ID: 15696394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
